Protein S Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9512R-Cy5.5 |
| Product Name | Protein S Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
IF
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Protein S/PROS |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 5627 |
| Swiss Prot | P07225 |
| Synonyms | Preproprotein S; Propiece of latent protein S; PROS 1; PROS; PROS_HUMAN; PROS1; Protein S alpha; Protein Sa; PS 21; PS 22; PS 23; PS 24; PS 25; PS 26; PS21; PS22; PS23; PS24; PS25; PS26; PSA; Vitamin K dependent protein S; Vitamin K-dependent protein S. |
| Background | Protein S (PROS) is a vitamin K-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated protein C (APC) and facilitates clearance of early apoptotic cells. In the plasma, circulating Protein S becomes inactive upon complexing with C4b-binding protein (C4BP); 60-70% of Protein S circulates in complex with C4BP. Calcium-dependent association of C4BP-Protein S with apoptotic cells influences the regulation of complement activation. Protein S has APC-independent anticoagulant activity through direct inhibition of prothrombin activation via interactions with Factor X A, Factor V A and phospholipids. Autosomal dominant Protein S deficiency (levels 15 to 37% of normal) correlates with severe recurrent venous thrombosis. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF | IHC-P1:50-200 |